Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: A randomised double-blind placebo-controlled study

European Journal of Endocrinology

Volumn 172, Issue 1, 2015, Pages 11-20

  Hove, K D ^a   Brons C ^a,c   Faerch K ^a   Lund, S S ^a   Rossing, P ^a,b,c   Vaag, A ^a,c  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR; YOGHURT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FACTORIAL ANALYSIS; FERMENTED PRODUCT; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; LACTOBACILLUS HELVETICUS; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; DAIRY PRODUCT; DIET THERAPY; FEMALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CULTURED MILK PRODUCTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84920379401     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0554     Document Type: Article

References (40)

1. Boelsma E & Kloek J. Lactotripeptides and antihypertensive effects: a critical review. British Journal of Nutrition 2009 101 776-786. (doi:10.1017/S0007114508137722)
2. Sipola M, Finckenberg P, Santisteban J., Korpela R, Vapaatalo H & Nurminen ML. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. Journal of Physiology and Pharmacology 2001 52 745-754.
3. Patel A, Group AC, MacMahon S, Chalmers J., Neal B, Woodward M, Billot L., Harrap S, Poulter N, Marre M et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 829-840. (doi:10.1016/S0140-6736(07)61303-8)
4. Usinger L, Reimer C & Ibsen H. Fermented milk for hypertension. Cochrane Database of Systematic Reviews 2012 4 CD008118. (doi:10.1002/14651858)
5. Padwal R & Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004 27 247-255. (doi:10.2337/diacare.27.1.247)
6. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004 64 2537-2565. (doi:10.2165/00003495-200464220-00004)
7. Group NS, McMurray JJ, Holman R.R., Haffner SM, Bethel MA, Holzhauer B, Hua T.A., Belenkov Y., Boolell M, Buse JB et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. New England Journal of Medicine 2010 362 1477-1490. (doi:10.1056/NEJMoa1001121)
8. Investigators DT, Bosch J, Yusuf S., Gerstein HC, Pogue J, Sheridan P, Dagenais G., Diaz R, Avezum A, Lanas F et al. Effect of ramipril on the incidence of diabetes. New England Journal of Medicine 2006 355 1551-1562. (doi:10.1056/NEJMoa065061)
9. Gobel RJ, Larsen N, Jakobsen M., Molgaard C & Michaelsen KF. Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. Journal of Pediatric Gastroenterology and Nutrition 2012 55 673-678. (doi:10.1097/MPG.0b013e318263066c)
10. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg R.M., Moller K., Svendsen KD, Jakobsen M & Pedersen BK. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. British Journal of Nutrition 2010 104 1831-1838. (doi:10.1017/S0007114510002874)
11. Laitinen K, Poussa T, Isolauri E & Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. British Journal of Nutrition 2009 101 1679-1687. (doi:10.1017/S0007114508111461)
12. Hove KD, Brons C, Faerch K., Lund SS, Petersen JS, Karlsen AE, Rossing P, Rehfeld JF & Vaag A. Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia 2013 56 22-30. (doi:10.1007/s00125-012-2714-y)
13. Usinger L, Jensen LT, Flambard B, Linneberg A & Ibsen H. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. Journal of Human Hypertension 2010 24 678-683. (doi:10.1038/jhh.2010.4)
14. Engberink MF, Schouten EG, Kok F.J., van Mierlo LA, Brouwer IA & Geleijnse JM. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension 2008 51 399-405. (doi:10.1161/HYPERTENSIONAHA. 107.098988)
15. van Mierlo L.A., Koning MM, van der Zander K & Draijer R. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies. American Journal of Clinical Nutrition 2009 89 617-623. (doi:10.3945/ajcn.2008.26918)
16. Cicero AF, Rosticci M, Veronesi M., Bacchelli S, Strocchi E, Melegari C., Grandi E & Borghi C. Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, crossover clinical trial. Journal of Medicinal Food 2010 13 1363-1368. (doi:10.1089/jmf.2009.0253)
17. Jauhiainen T, Vapaatalo H, Poussa T., Kyronpalo S, Rasmussen M & Korpela R. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. American Journal of Hypertension 2005 18 1600-1605. (doi:10.1016/j.amjhyper.2005.06.006)
18. Cicero AF, Gerocarni B, Laghi L & Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. Journal of Human Hypertension 2011 25 425-436. (doi:10.1038/jhh.2010.85)
19. Pripp AH. Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials. Food & Nutrition Research 2008 52 1-9. (doi:10.3402/fnr.v52i0.1641)
20. Xu JY, Qin LQ, Wang P.Y., Li W & Chang C. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition 2008 24 933-940. (doi:10.1016/j.nut.2008.04.004)
21. Cicero AF, Aubin F, Azais-Braesco V & Borghi C. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. American Journal of Hypertension 2013 26 442-449. (doi:10.1093/ajh/hps044)
22. Fuglsang A, Nilsson D & Nyborg NC. Cardiovascular effects of fermented milk containing angiotensin-converting enzyme inhibitors evaluated in permanently catheterized, spontaneously hypertensive rats. Applied and Environmental Microbiology 2002 68 3566-3569. (doi:10.1128/AEM.68.7.3566-3569.2002)
23. Pierdomenico SD, Bucci A, Lapenna D., Cuccurullo F & Mezzetti A. Heart rate in hypertensive patients treated with ACE inhibitors and long-acting dihydropyridine calcium antagonists. Journal of Cardiovascular Pharmacology 2002 40 288-295. (doi:10.1097/00005344-200208000-00014)
24. Jensen MT, Marott JL, Allin K.H., Nordestgaard BG & Jensen GB. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study. European Journal of Preventive Cardiology 2012 19 102-108. (doi:10.1177/1741826710394274)
25. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Progress in Cardiovascular Diseases 2009 52 46-60. (doi:10.1016/j.pcad.2009.05.005)
26. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America 2004 88 787-835, ix. (doi:10.1016/j.mcna.2004.04.013)
27. Dahlof B, Devereux RB, Kjeldsen S.E., Julius S., Beevers G, de Faire U, Fyhrquist F, Ibsen H., Kristiansson K, Lederballe-Pedersen O et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 995-1003. (doi:10.1016/S0140-6736(02)08089-3)
28. Hansson L, Hedner T, Lindholm L., Niklason A, Luomanmaki K, Niskanen L., Lanke J, Dahlof B, de Faire U, Morlin C et al. The Captopril Prevention Project (CAPPP) in hypertension - baseline data and current status. Blood Pressure 1997 6 365-367. (doi:10.3109/08037059709062096)
29. Julius S, Weber MA, Kjeldsen S.E., McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork M.A., Hua TA, Amerena J et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006 48 385-391. (doi:10.1161/01.HYp.0000236119.96301.f2)
30. Yusuf S, Gerstein H, Hoogwerf B., Pogue J, Bosch J, Wolffenbuttel B.H., Zinman B & HS Investigators. Ramipril and the development of diabetes. Journal of the American Medical Association 2001 286 1882-1885. (doi:10.1001/jama.286.15.1882)
31. Jauch KW, Hartl W, Guenther B., Wicklmayr M, Rett K & Dietze G. Captopril enhances insulin responsiveness offorearm muscle tissue in non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation 1987 17 448-454. (doi:10.1111/j.1365-2362.1987.tb01141.x)
32. Torlone E, Rambotti AM, Perriello G, Botta G., Santeusanio F, Brunetti P & Bolli GB. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991 34 119-125. (doi:10.1007/BF00500383)
33. Suzuki K, Nakagawa O & Aizawa Y. Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clinical and Experimental Hypertension 2008 30 309-314. (doi:10.1080/10641960802269927)
34. Festa ADARJ, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP & Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000 102 42-47. (doi:10.1161/01.CIR.102.1.42)
35. Libby P, Ridker PM & Maseri A. Inflammation and atherosclerosis. Circulation 2002 105 1135-1143. (doi:10.1161/hc0902.104353)
36. Panwar H, Rashmi HM, Batish VK & Grover S. Probiotics as potential biotherapeutics in the management of type 2 diabetes - prospects and perspectives. Diabetes/Metabolism Research and Reviews 2013 29 103-112. (doi:10.1002/dmrr.2376)
37. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. Journal of Clinical Endocrinology and Metabolism 2009 94 3171-3182. (doi:10.1210/jc.2008-2534)
38. Haro C, Villena J, Zelaya H., Alvarez S & Aguero G. Lactobacillus casei modulates the inflammation-coagulation interaction in a pneumo-coccal pneumonia experimental model. Journal of Inflammation 2009 6 28. (doi:10.1186/1476-9255-6-28)
39. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997 95 1-4. (doi:10.1161/01.CIR.95.1.1)
40. Beermann C & Hartung J. Physiological properties of milk ingredients released by fermentation. Food & Function 2013 4 185-199. (doi:10.1039/c2fo30153a)